Is the business good?
How good a business is AUPH?
Aurinia Pharmaceuticals Inc. earns 19% on the capital it employs against a 9.0% cost of capital, so the business is worth more the bigger it gets.
19%
Return on invested capital · cost of capital 9.0% · 9.7 points above what the capital costs: growth creates value
- Operating margin
- 42%
Operating margin · Biotechnology median −72% · 12 months to Q1 2026
- Share count, year on year
- −3.9%
Share count, year on year · bought back, each share owns more of the company
- R&D as % of revenue
- 11%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −208% |
| FY2021 | −396% |
| FY2022 | −83% |
| FY2023 | −52% |
| FY2024 | −2.0% |
| FY2025 | 37% |
Details›
- Gross margin12 months to Q1 2026
- 90%
- Operating margin12 months to Q1 2026
- 42%
- Net margin12 months to Q1 2026
- 100%
- R&D as % of revenue
- 11%
- Revenue, trailing twelve months
- $298M
- Net income, trailing twelve months
- $298M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 19%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.